Bayer to take part in NanoCare project
German pharmaceutical group Bayer says it is participating in NanoCare, a government-funded research project that aims to further enhance scientific analysis of nanomaterials.
Backed by the German Federal Ministry of Education and Research, the initiative is focusing on the properties of nanoparticles, atom- or molecule-sized particles, to ensure that they pose no risk to humans and the environment when used in chemical materials.
As a pioneer in the use and application of miniscule particles in structures on a scale of up to 100 nanometers, Bayer is keen to tap the innovative potential of nanotechnology and, with this in mind, the group is pressing ahead with research into the safe handling of nanomaterials.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze